At a glance
ClinicalIndex Comparison Record- ✓Age 18 years or older
- ✓Confirmed diagnosis of epilepsy by study neurologist
- ✓Stable doses of antiepileptic and antidepressant medications for at least 1 month
- ✓Able to safely undergo MRI assessment
- ✕Significant cognitive impairment (MoCA <23)
- ✕History of major psychiatric disorder (schizophrenia, bipolar disorder, substance use disorder except caffeine/nicotine)
- ✕Unstable medical comorbidities
- ✕Active or imminent suicidality (QIDS item 12 >2 or MINI Suicidality module >16)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Feasibility of Accelerated Low-Frequency Transcranial Magnetic Stimulation for Medication-Resistant Depression in Patients With Epilepsy
In Brief
A clinical study evaluating Transcranial Magnetic Stimulation for Epilepsy and Depressions, Refractory. Completed, enrolled 15 participants across 1 site.
Detailed Summary
The purpose of this study is to determine if low-frequency transcranial magnetic stimulation (TMS) is safe and feasible for treating depressive symptoms in patients with epilepsy. Patients will receive an accelerated protocol of TMS consisting of three consecutive days of treatment. Patients will have in-person follow up visits after one month and again after six months.
Study Details
Timeline
Interventions
Repetitive transcranial magnetic stimulation (TMS) is a focal, nonpharmacological, noninvasive method for stimulating the brain and modulating neural network activity. To administer TMS, an electromagnetic coil is placed on the scalp, and uses electrical current to create magnetic fields that depolarize or hyperpolarize neurons in the brain.